Contact Us
Drug Search Results
More Filters [+]

Lifirafenib

Alternative Names: lifirafenib, bgb-283
Latest Update: 2024-04-15
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: BeiGene
Company Location: GRAND CAYMAN E9 KY1-1108
Company CEO: John V. Oyler
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Lifirafenib

Countries in Clinic: Australia, United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
BGB-283/PD-0325901-AU-001

P1

Recruiting

Oncology Solid Tumor Unspecified

2025-09-30

Recent News Events

Date

Type

Title

04/15/2024

PubMed

 T cell-mediated tumor killing sensitivity gene signature-based prognostic score for acute myeloid leukemia.

01/08/2024

News Article

 SpringWorks Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference

05/04/2023

News Article

 BeiGene Reports First Quarter 2023 Financial Results and Corporate Developments

04/17/2023

News Article

 BeiGene and SpringWorks Present Clinical Data on Lifirafenib, in Combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

04/17/2023

News Article

 SpringWorks and BeiGene Present Clinical Data on Lifirafenib, in combination with Mirdametinib, in Patients with Advanced or Refractory Solid Tumors with MAPK Pathway Aberrations at the American Association for Cancer Research Annual Meeting 2023

10/01/2021

PubMed

 Blockade of mutant RAS oncogenic signaling with a special emphasis on KRAS.

10/01/2020

PubMed

 Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions